Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.
Drug repositioning
Drug repurposing
Nanocarriers
Nanoparticles
Parkinson’s disease
Pharmaceutical nanotechnology
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
19
05
2022
accepted:
31
08
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) significantly affects patients' quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors "Parkinson's disease" and "drug repositioning" or "drug repurposing". We identified 28 drugs as potential candidates, and six of them were found in repositioning clinical trials for PD. However, a limitation of many of these drugs to achieve therapeutic success is their inability to cross the blood-brain barrier (BBB), as is the case with nilotinib, which has shown promising outcomes in clinical trials. We suggest reformulating these drugs in biodegradable nanoparticles (NPs) based on lipids and polymers to perform future trials. As a complementary strategy, we propose functionalizing the NPs surface by adding materials to the surface layer. Among other advantages, functionalization can promote efficient crossing through the BBB and improve the affinity of NPs towards certain brain regions. The main parameters to consider for the design of NPs targeting the central nervous system are highlighted, such as size, PDI, morphology, drug load, and Z potential. Finally, current advances in the use of NPs for Parkinson's disease are cited.
Identifiants
pubmed: 36109747
doi: 10.1186/s12951-022-01612-5
pii: 10.1186/s12951-022-01612-5
pmc: PMC9479294
doi:
Substances chimiques
Lipids
0
Pharmaceutical Preparations
0
Polymers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
413Informations de copyright
© 2022. The Author(s).
Références
Eur J Neurol. 2016 Oct;23(10):1556-65
pubmed: 27425586
Sci Rep. 2015 May 13;5:10048
pubmed: 25970096
Pharmaceutics. 2018 Jul 08;10(3):
pubmed: 29986543
J Pharm Pharmacol. 2017 Feb;69(2):143-150
pubmed: 28033667
Int J Clin Pract. 2011 Dec;65(12):1289-94
pubmed: 22093536
J Parkinsons Dis. 2017;7(4):589-601
pubmed: 29103051
Drug Discov Today. 2015 Jul;20(7):824-37
pubmed: 25701281
Front Aging Neurosci. 2020 Feb 13;12:31
pubmed: 32116655
JAMA Neurol. 2021 Mar 1;78(3):312-320
pubmed: 33315105
Int J Pharm. 2006 Mar 9;310(1-2):213-9
pubmed: 16426779
Eur J Pharm Biopharm. 2014 May;87(1):19-29
pubmed: 24607790
Sci Rep. 2020 Nov 20;10(1):20258
pubmed: 33219264
Neurol India. 2017 Nov-Dec;65(6):1271-1279
pubmed: 29133700
Exp Neurobiol. 2014 Sep;23(3):246-52
pubmed: 25258572
Eur J Pharm Sci. 2013 Feb 14;48(3):393-405
pubmed: 23266466
Chem Phys Lipids. 2021 May;236:105060
pubmed: 33582127
J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):47-57
pubmed: 19778266
Nat Commun. 2019 Apr 18;10(1):1817
pubmed: 31000720
Clin Geriatr Med. 2020 Feb;36(1):1-12
pubmed: 31733690
N Engl J Med. 2004 Dec 9;351(24):2498-508
pubmed: 15590952
Biomaterials. 2013 Jan;34(3):794-806
pubmed: 23103156
J Pharm Pharm Sci. 2021;24:509-532
pubmed: 34644523
Eur J Pharm Biopharm. 2002 Sep;54(2):165-70
pubmed: 12191688
CNS Drugs. 2018 Aug;32(8):747-761
pubmed: 30066310
CNS Neurosci Ther. 2016 Oct;22(10):817-23
pubmed: 27350533
J Gene Med. 2009 Sep;11(9):754-63
pubmed: 19554623
Lancet. 2014 Feb 8;383(9916):533-40
pubmed: 24183563
Sci Rep. 2017 Feb 03;7:41755
pubmed: 28155912
Hum Mol Genet. 2018 Nov 15;27(22):3974-3985
pubmed: 30137437
Int J Nanomedicine. 2016 Jan 08;11:179-200
pubmed: 26811677
J Am Chem Soc. 2010 Mar 31;132(12):4259-65
pubmed: 20218672
Acta Neuropathol. 1996;91(6):566-72
pubmed: 8781654
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109716
pubmed: 31349431
J Control Release. 2019 Jan 28;294:17-26
pubmed: 30529726
Front Microbiol. 2016 May 02;7:607
pubmed: 27330535
Drug Discov Today. 2016 Jul;21(7):1155-61
pubmed: 27196527
Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37
pubmed: 19376175
Photodiagnosis Photodyn Ther. 2018 Sep;23:212-217
pubmed: 29928992
J Neurol. 2021 May;268(5):1981-1994
pubmed: 33141248
Sci Rep. 2014 May 02;4:4874
pubmed: 24786396
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1428-1436
pubmed: 31007068
Free Radic Res. 2017 Jun;51(6):633-645
pubmed: 28770670
Turk J Pharm Sci. 2020 Oct;17(5):492-499
pubmed: 33177929
Science. 2017 Sep 1;357(6354):891-898
pubmed: 28860381
Int J Biol Macromol. 2017 Dec;105(Pt 1):416-421
pubmed: 28711612
J Biol Chem. 2017 Sep 22;292(38):15731-15743
pubmed: 28798236
Comput Struct Biotechnol J. 2020 Apr 13;18:1043-1055
pubmed: 32419905
Sci Rep. 2018 Jun 12;8(1):8959
pubmed: 29895906
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808
pubmed: 32576618
Eur J Pharm Biopharm. 2014 May;87(1):114-24
pubmed: 24378615
Int J Pharm. 2020 May 15;581:119291
pubmed: 32259638
AAPS PharmSciTech. 2020 Jun 11;21(5):170
pubmed: 32529303
Int J Pharm. 2020 Nov 30;590:119957
pubmed: 33035606
NPJ Parkinsons Dis. 2020 Jul 9;6:15
pubmed: 32665974
Neuromolecular Med. 2018 Mar;20(1):1-17
pubmed: 29305687
Methods Enzymol. 2012;509:61-85
pubmed: 22568901
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
Biomacromolecules. 2012 Apr 9;13(4):1067-73
pubmed: 22409486
Neuropharmacology. 2019 Mar 15;147:4-10
pubmed: 30165077
Pharmacol Rep. 2020 Oct;72(5):1397-1406
pubmed: 32207092
J Cell Mol Med. 2019 Dec;23(12):8505-8510
pubmed: 31560168
Front Oncol. 2017 Nov 14;7:273
pubmed: 29184849
Front Neurol. 2019 Apr 17;10:351
pubmed: 31057473
Drugs Aging. 2019 Mar;36(3):189-202
pubmed: 30623310
Assay Drug Dev Technol. 2017 Apr;15(3):106-112
pubmed: 28418693
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Biochem J. 2004 Jan 1;377(Pt 1):159-69
pubmed: 14505488
Int J Nanomedicine. 2020 Dec 24;15:10453-10467
pubmed: 33380795
J Drug Target. 2011 Feb;19(2):125-32
pubmed: 20387992
Parkinsons Dis. 2020 Mar 26;2020:9131474
pubmed: 32300476
Mol Pharm. 2019 Feb 4;16(2):518-532
pubmed: 30601014
Neurotherapeutics. 2018 Oct;15(4):1063-1081
pubmed: 29987762
Int J Environ Res Public Health. 2016 Sep 03;13(9):
pubmed: 27598189
Mov Disord. 2017 Nov;32(11):1547-1556
pubmed: 28631864
Pharmacogenomics. 2014 Jun;15(9):1253-71
pubmed: 25141900
Drug Deliv. 2016;23(2):395-404
pubmed: 24865287
Mol Pharm. 2014 Dec 1;11(12):4363-73
pubmed: 25327847
J Pharm Pharm Sci. 2009;12(3):288-311
pubmed: 20067706
JAMA Neurol. 2017 Feb 01;74(2):216-224
pubmed: 27942720
Expert Opin Drug Discov. 2020 Apr;15(4):397-401
pubmed: 31847616
Antioxid Redox Signal. 2016 Jul 10;25(2):61-77
pubmed: 27009601
Adv Drug Deliv Rev. 2007 Aug 10;59(8):748-58
pubmed: 17659804
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):221-30
pubmed: 22458623
Ann Neurol. 2015 Jun;77(6):930-41
pubmed: 25820831
Curr Med Chem. 2019;26(28):5340-5362
pubmed: 30027839
Drug Deliv. 2015;22(6):823-36
pubmed: 24725026
Nucleic Acids Res. 2011 Jan;39(Database issue):D1060-6
pubmed: 21071407
Neurology. 2009 May 26;72(21 Suppl 4):S1-136
pubmed: 19470958
Nanomedicine. 2018 Nov;14(8):2609-2618
pubmed: 30171904
Drug Deliv. 2018 Nov;25(1):1694-1705
pubmed: 30394120
Nanomaterials (Basel). 2018 Mar 20;8(3):
pubmed: 29558440
Exp Neurol. 2020 Nov;333:113413
pubmed: 32717354
Mov Disord. 2016 Nov;31(11):1602-1609
pubmed: 27430479
J Med Chem. 2019 Nov 14;62(21):9824-9836
pubmed: 31603678
J Am Chem Soc. 2005 Jun 8;127(22):8168-73
pubmed: 15926845
JAMA Neurol. 2020 Mar 1;77(3):309-317
pubmed: 31841599
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Nanotechnology. 2019 Nov 8;30(45):455102
pubmed: 31365912
Cell Res. 2019 Apr;29(4):313-329
pubmed: 30858560
J Parkinsons Dis. 2019;9(1):157-171
pubmed: 30741689
Eur J Neurosci. 2019 Mar;49(6):869-882
pubmed: 30022547
Int J Nanomedicine. 2017 May 31;12:4085-4109
pubmed: 28615938
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
Biomater Res. 2019 Nov 21;23:20
pubmed: 31832232
J Pharm Pharm Sci. 2017;20(0):226-238
pubmed: 28719359
Curr Drug Metab. 2014 Feb;15(2):129-81
pubmed: 24694231
Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180246
pubmed: 30994800
J Neural Transm (Vienna). 2017 Aug;124(8):901-905
pubmed: 28150045
Gels. 2020 Feb 04;6(1):
pubmed: 32033057
Sci Rep. 2019 Jun 6;9(1):8336
pubmed: 31171821
CNS Neurol Disord Drug Targets. 2018 Apr 26;17(1):14-21
pubmed: 28571531
ACS Chem Neurosci. 2017 Apr 19;8(4):860-865
pubmed: 27983793
Front Aging Neurosci. 2014 May 13;6:87
pubmed: 24860498
Neurobiol Aging. 2016 Dec;48:61-71
pubmed: 27644075
Front Aging Neurosci. 2018 Apr 17;10:109
pubmed: 29719505
Drug Dev Ind Pharm. 2020 Jul;46(7):1063-1072
pubmed: 32406290
Pharm Res. 1996 Dec;13(12):1838-45
pubmed: 8987081
Int J Pharm. 2019 Mar 25;559:360-372
pubmed: 30721725
J Control Release. 2016 Aug 10;235:34-47
pubmed: 27208862
Drug Deliv Transl Res. 2019 Oct;9(5):879-890
pubmed: 30887226
Colloids Surf B Biointerfaces. 2008 Feb 15;61(2):132-7
pubmed: 17888636
Neurobiol Dis. 2020 Feb;134:104700
pubmed: 31809788
Nanomedicine. 2018 Feb 21;14(4):1123-1136
pubmed: 29474924
Curr Clin Pharmacol. 2020;15(1):20-29
pubmed: 31272358
Neuropharmacology. 2017 Oct;125:396-407
pubmed: 28807678
Pharm Res. 2013 Oct;30(10):2549-59
pubmed: 23703371
Expert Opin Pharmacother. 2018 Nov;19(16):1821-1828
pubmed: 30232916
Environ Health Perspect. 2011 Jun;119(6):866-72
pubmed: 21269927
Expert Opin Drug Metab Toxicol. 2016;12(4):433-48
pubmed: 26910127
Brief Bioinform. 2011 Jul;12(4):303-11
pubmed: 21690101
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5
pubmed: 17267609
Beilstein J Nanotechnol. 2020 Jun 4;11:866-883
pubmed: 32551212
Drug Deliv. 2019 Dec;26(1):700-707
pubmed: 31290705
Int J Pharm. 2006 Apr 7;312(1-2):179-86
pubmed: 16469459
ACS Appl Mater Interfaces. 2018 Nov 21;10(46):39557-39569
pubmed: 30352150
Chem Commun (Camb). 2019 Sep 21;55(74):11052-11055
pubmed: 31453599